Literature DB >> 27775069

Immunotherapy: Checkpoint barriers.

Anna Dart.   

Abstract

Year:  2016        PMID： 27775069     DOI： 10.1038/nrc.2016.118

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


× No keyword cloud information.
  2 in total

1.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Authors:  Jianjun Gao; Lewis Zhichang Shi; Hao Zhao; Jianfeng Chen; Liangwen Xiong; Qiuming He; Tenghui Chen; Jason Roszik; Chantale Bernatchez; Scott E Woodman; Pei-Ling Chen; Patrick Hwu; James P Allison; Andrew Futreal; Jennifer A Wargo; Padmanee Sharma
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

2.  Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy.

Authors:  Nadeem Riaz; Jonathan J Havel; Sviatoslav M Kendall; Vladimir Makarov; Logan A Walsh; Alexis Desrichard; Nils Weinhold; Timothy A Chan
Journal:  Nat Genet       Date:  2016-09-26       Impact factor: 38.330
  2 in total
  2 in total

1.  A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy.

Authors:  Yu Mi; Christof C Smith; Feifei Yang; Yanfei Qi; Kyle C Roche; Jonathan S Serody; Benjamin G Vincent; Andrew Z Wang
Journal:  Adv Mater       Date:  2018-04-25       Impact factor: 30.849

2.  Sunitinib and Sorafenib Modulating Antitumor Immunity in Hepatocellular Cancer.

Authors:  Dai Liu; Xiaoqiang Qi; Yariswamy Manjunath; Eric T Kimchi; Lixin Ma; Jussuf T Kaifi; Kevin F Staveley-O'Carroll; Guangfu Li
Journal:  J Immunol Res Ther       Date:  2018-06-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.